Serious games for patients with mild cognitive impairment (MCI)

Development and Evaluation of Serious Games for Diagnosis and Cognitive Improvement of Patients with Mild Cognitive Impairment(MCI)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211020052824N1

Enrollment

Registered

2021-11-21

Start date

2021-11-06

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment. Mild cognitive impairment, so stated

Interventions

Intervention group: The participants will be asked to play parts of the game as prescribed by a neurologist, three days a week, at least 45 min each time, for three months at home since the appointed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A neurologist should confirm the initial diagnosis of MCI in patients. Participants should have almost the same medical test results. They should be willing to participate in the study and complete the informed consent form.

Exclusion criteria

Exclusion criteria: Participants have disabilities in the upper limbs. participants have other mental health problems according to the neurologist.

Design outcomes

Primary

Measure	Time frame
Mini–Mental State Examination (MMSE) test score. Timepoint: At beginning of study and after three months. Method of measurement: This outcome will be measured using standard Mini–Mental State Examination (MMSE) test. MMSE is the most common test applied to assess cognitive impairment. MMSE has been translated into Persian and validated for Iranians. Implementing MMSE will be accomplished by a neurologist in Brain and Cognition Clinic in Iran University of Medical Sciences at the beginning of the study. At the end of three months, MMSE will be retaken from the participants by the same neurologist at the same location.;Addenbrooke’s Cognitive Examination (ACE_R) test score. Timepoint: At beginning of study and after three months. Method of measurement: This outcome will be measured ?sing Addenbrooke’s Cognitive Examination-Revised version tools. This test examines memory, language, and visual-spatial skills more broadly than MMSE and includes verbal fluency components. ACE-R has been translated into Persian and validated for Iranians. Implementing ACE-R will be accomplished by a neurologist in Brain and Cognition Clinic in Iran University of Medical Sciences at the beginning of the study. At the end of three months, ACE-R will be retaken from the participants by the same neurologist at the same location.	—

Measure

Time frame

Mini–Mental State Examination (MMSE) test score. Timepoint: At beginning of study and after three months. Method of measurement: This outcome will be measured using standard Mini–Mental State Examination (MMSE) test. MMSE is the most common test applied to assess cognitive impairment. MMSE has been translated into Persian and validated for Iranians. Implementing MMSE will be accomplished by a neurologist in Brain and Cognition Clinic in Iran University of Medical Sciences at the beginning of the study. At the end of three months, MMSE will be retaken from the participants by the same neurologist at the same location.;Addenbrooke’s Cognitive Examination (ACE_R) test score. Timepoint: At beginning of study and after three months. Method of measurement: This outcome will be measured ?sing Addenbrooke’s Cognitive Examination-Revised version tools. This test examines memory, language, and visual-spatial skills more broadly than MMSE and includes verbal fluency components. ACE-R has been translated into Persian and validated for Iranians. Implementing ACE-R will be accomplished by a neurologist in Brain and Cognition Clinic in Iran University of Medical Sciences at the beginning of the study. At the end of three months, ACE-R will be retaken from the participants by the same neurologist at the same location.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Sheikhtaheri

Iran University of Medical Sciences

Sheikhtaheri.a@iums.ac.ir+98 21 8879 4301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026